CTLA4 and lymphedema: While the prevalence under anti-PD1 therapy was comparable to the prevalence observed in patients without treatment (19% anti-PD1 treatment vs. 18.8% only LAD/untreated), the anti-CTLA4 treatment showed a remarkable and significant reduction of lymphedema risk.